Clin Lab. 2023 Oct 1;69(10). doi: 10.7754/Clin.Lab.2023.230204.
Early determination of the prognosis in hepatitis B virus-associated decompensated cirrhosis (HBV-DC) patients is important to improve their survival. The present study aimed to determine the predictive ability of monocyte-to-albumin ratio (MAR) for poor prognosis in HBV-DC.
This work recruited 263 HBV-DC patients admitted to our hospital from November 2020 through March 2022. The clinical data, laboratory parameters, and clinical prognosis of the patients were retrospectively collected and analyzed.
Mortality at 30 days was 20.2% (53/263). MAR was found to be higher in the non-survivors compared with the survivors. Higher MAR was associated with higher 30-day mortality, and MAR was identified as an independent predictor of poor prognosis in HBV-DC. Furthermore, the predictive values between MAR and Model for End-Stage Liver Disease score are comparable.
MAR could be potentially used as a novel prognostic marker to predict prognosis in HBV-DC.
早期确定乙型肝炎病毒相关失代偿性肝硬化（HBV-DC）患者的预后对于改善其生存率非常重要。本研究旨在确定单核细胞-白蛋白比值（MAR）对 HBV-DC 不良预后的预测能力。
本研究纳入了 2020 年 11 月至 2022 年 3 月期间我院收治的 263 例 HBV-DC 患者。回顾性收集并分析了患者的临床资料、实验室参数和临床预后。
30 天死亡率为 20.2%（53/263）。与存活者相比，非存活者的 MAR 更高。较高的 MAR 与 30 天死亡率的增加相关，MAR 被确定为 HBV-DC 不良预后的独立预测因子。此外，MAR 与终末期肝病模型评分之间的预测价值相当。
MAR 可作为一种新型预后标志物，用于预测 HBV-DC 的预后。
